Nxera Pharma和Holling生物药厂合作伙伴,将失眠药物Daridorexant带入台湾市场。 Nxera Pharma and Holling Bio-Pharma partner to bring insomnia drug Daridorexant to Taiwan market.

Nxera Pharma与Holling Bio-Pharma合作,在台湾将失眠治疗达里多克斯坦(Daridorexant)商业化。 Nxera Pharma has partnered with Holling Bio-Pharma to commercialize Daridorexant, an insomnia treatment, in Taiwan. 预计于2025年年中提交申请,如经批准,将于2026年年中启动,日本已经提供达里多脱脂剂。 Expected to file in mid-2025 and launch mid-2026 if approved, Daridorexant is already available in Japan. 该协议认为Nxera供应该药物,而Holling负责监管和商业活动,Nxera则接受付款和特许使用费。 The agreement sees Nxera supplying the drug, while Holling handles regulatory and commercial activities, with Nxera receiving payments and royalties. 台湾约400万至500万成年人患有失眠症。 Insomnia affects around 4-5 million adults in Taiwan.